The role of oxidative stress in depressive disorders

Current Pharmaceutical Design

Volumn 18, Issue 32, 2012, Pages 5890-5899

  Michel, Tanja Maria ^a   Pülschen, Dietrich ^a   Thome, Johannes ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

Author keywords

Affective disorder; Antioxidants; Catalase antidepressants; Depression; Free radicals; Glutathione; Gluthatione peroxidase; Oxidative stress; Prooxidants; Psychiatry; Superoxide; Superoxide dismutase; Xanthine oxidase

Indexed keywords

ANTIOXIDANT; CITALOPRAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ACETYLSALICYLIC ACID; ALDEHYDE DEHYDROGENASE; AMINE OXIDASE (FLAVIN CONTAINING); AMITRIPTYLINE; ASCORBIC ACID; CATALASE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; HYDROGEN PEROXIDE; LOSARTAN; MALONALDEHYDE; MONOAMINE; NITROGEN OXIDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; SUPEROXIDE DISMUTASE; TRANYLCYPROMINE; UBIDECARENONE; UNINDEXED DRUG; XANTHINE OXIDASE;

DEPRESSION; EMOTIONAL STRESS; FRONTAL CORTEX; GLIA CELL; HUMAN; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MEMBRANE DAMAGE; MOOD DISORDER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANTIOXIDANT ACTIVITY; BRAIN SIZE; COGNITIVE DEFECT; CONCENTRATION LOSS; DRUG MECHANISM; HIPPOCAMPUS; MAJOR DEPRESSION; MEMORY DISORDER; NERVE CELL; NERVE CELL PLASTICITY; NEUROTOXICITY; PATHOGENESIS;

ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; BRAIN; DEPRESSION; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84867696554     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. International Statistical Classification of Diseases and related health problems, tenth revision, ICD 10; WHO, 1992
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349: 1436-42.
3. Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a metaanalysis. Am J Psychiatry 2004; 161: 598-607.
4. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002; 125: 1428-1449.
5. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biological Psychiatry 1999; 45: 1085-1098.
6. Rajkowska G., Halaris A., Selemon LD. Reductions on neuronal and glial density and characterize the dorsolateral prefrontal cortex in bipolar disorder. Biological Psychiatry 2001; 49: 741-752.
7. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulated cortex in major depressive disorder. Archives of General Psychiatry 2001; 58: 545-553.
8. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cerebral Cortex 2002; 12: 386-394.
9. Bowley MP, Drevets WC, Ongur D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biological Psychiatry 2002; 52: 404-412.
10. Michel TM, Frangou S, Thiemeyer D, et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder - a post-mortem study. Psychiatry Research 2007; 151: 145-50.
11. Michel TM, Thome J, Martin D, et al. Cu, Zn-and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transmission 2004; 111: 1191-1201.
12. Michel TM, Camara S, Tatschner T, et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychiatry 2010; 11: 314-20.
13. Halliwell B, Gutteridge JMC. Free Radical in Biology and Medicine. Oxford: Clarendon Press, 1985.
14. Fridovich, I. Biological effects of the superoxide radical. Archives of Biochemistry and Biophysics 1986; 247: 1-11.
15. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine, ed 2. Oxford: Clarendon Press 1989.
16. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002; 125: 1428-1449.
17. Hille R. Molybdenum-containing hydroxylases. Archives of biochemistry and biophysics 2005; 433: 107-116.
18. Brown JM, Terada LS, Grosso MA, et al. Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused, rat hearts. J Clin Invest 1988; 81:1297-301.
19. Terada LS, Beehler CJ, Banerjee A, et al. Peroxia and self-or neutrophil-generated O2 metabolites inactivate xanthine oxidase. J Appl Physiol 1988; 65: 2349-53.
20. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159-163.
21. Zweier JL, Kuppusamy P, Lutty GA. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues. Proc Natl Acad Sci USA 1988; 85: 4046-4050.
22. Winterbourn CC. Superoxide as an intracellular radical sink. Free Radical Biology & Medicine 1993; 14: 85-90.
23. Gsell W, Conrad R, Hickethier M, et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J. Neurochem 1995; 64, 1216-1223.
24. Durany N, Münch G, Michel TM, Riederer P. Investigations on oxidative stress and therapeutical implications in dementia. European Archives of Psychiatry and Neurological Sciences 1999; 249: 68-73 (Suppl).
25. Goetz ME, Kunig G, Riederer P, Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacology and Therapeutics 1994; 63: 37-122.
26. Grünblatt E, Mandel S, Jacob-Hirsch J, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-protea-some, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transmission 2004; 111: 1543-1573.
27. Koutsillieri E, Scheller C, Grünblatt E, Nara K, Li J, Riederer P. Free radicals in Parkinson's disease. J Neurology Supplement 2002; 249: 1-5.
28. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. Journal Neurochemistry 1989; 53: 692-697.
29. Goetz ME, Freyberger A, Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transmission 1990; Supplementum 1990; 29: 241-249.
30. Riederer P, Lange KW. Pathogenesis of Parkinson's disease. Current Opinion in Neurology and Neurosurgery 1992; 5: 295-300.
31. Riederer P, Lange KW, Youdim MB. Recent advances in pharmacological therapy of Parkinson's disease. Advances in Neurology 1993; 60: 626-635.
32. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Znsuperoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62.
33. Hashimoto E, Zielke B, Wiesbeck GA, Riederer P. Oxidative-stress associated parameters (lactoferrin, superoxide dismutases) in serum of patients with Alzheimers's disease. Life Sciences 1997; 60: 13-19.
34. Retz W, Gsell W, Munch G, Rosler M, Riederer P. Free radicals in Alzheimer's disease. J Neural Transmission 1998; Supplementum 54: 221-236.
35. Koutsillieri E, Scheller C, Tribl F, Riederer P. Degeneration of neuronal cells due to oxidative stress-microglial contribution. Parkinsonism and Related Disorder 2002; 8: 401-6.
36. Noor R, Mittal S, Iqbal J. Superoxide dismutase applications and relevance to human diseases. Medical Science Monitor: International Medical J Experimental and Clinical Research 2002; 8: 210-215.
37. Michel TM, Thome J, Martin D, et al. Cu, Zn-and Mn-superoxide dismutase levels in brains of patients with schizophrenic psychosis. J Neural Transmission 2004; 111: 1191-1201.
38. Abraham S, Soundararajan CC, Vivekanandhan S, Behari M. Erythrocyte antioxidant enzymes in Parkinson's disease. Indian J Medical Research 2005; 121: 111-115.
39. Gruenblatt E, Schlosser R, Fischer P, et al. Oxidative stress related markers in the "VITA" and the cenenarian projects. Neurobiology of Aging 2005; 26: 429-438.
40. Michel TM, 2010 Habilitationsschrift Oxidativer Stress bei psychischen Erkrankungen.
41. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega 3-fetty acid levels in red blood cell membranes of depressive patients. Biological psychiatry 1998; 43: 315-319.
42. Bilici M, Efe H, Koroglu MA, Uyudu HA, Bekaroglu M, Deger O. Anti-oxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affective Disorders 2001; 64: 43-51.
43. Lukash AI, Zaika VG, Kucherenko AO, Miliutina NP, 2002. Free radical processes and antioxidant system in depression and treatment efficiency. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakove/Ministerstvo ydravookhraneniia i meditsiniskoi promyshlennosti rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov Vserossiiskoe obshchestvo psikhiatrov 2002; 102: 41-44.
44. Halliwell B, Gutteridge JM. The definition and measurement of antioxidants in biological systems. Free Radic Biol Med 1995; 18: 125-6.
45. Peet M, Murphy B, Shay J, Horrobin D. Deplation of omega 3-fetty acid levels in red blood cell membranes of depressive patients. Biological psychiatry 1998; 43: 315-319.
46. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Human Psychopharmacology 2007; 22: 67-73.
47. Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord 2004; 80: 249-256.
48. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-20-deoxyguanosine in clinical depression. Psychosom. Med 2006; 68: 1-7.
49. Bilici M, Efe H, Koroglu, MA, Uydu HA, Bekaraglu G, Deger, O. Anti-oxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect Disord 2001; 46: 43-51.
50. Sarandol A, Sarandol E, Eker SS, et al. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/ arylesterase activities in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psych 2006; 30: 1103-108.
51. Talarowska M, Galecki P, Maes M, et al. Malondialdehyde plasma concentration correlates with declarative and working memory in patients with recurrent depressive disorder. Mol Biol Rep 2012; 39: 5359-5366.
52. Halliwell, B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc. Res 2000; 47: 410-418.
53. Patrignani P, Tacconelli S. Isoprostanes and other markers of peroxidation in atherosclerosis. Biomarkers 2005;10 Suppl 1: 24-29.
54. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-513.
55. Dimopoulos N, Piperi C, Psarra V, Lea RW, Kalofoutis A. Increased plasma levels of 8-iso-PGF2a and IL-6 in an elderly population with depression. Psychiatry Res 2008; 161: 59-66.
56. Yager S, Forlenza MJ, Miller GE. Depression and oxidative damage to lipids. Psychoneuroendocrin 2010; 35: 1356-1362.
57. Ende G, Demirakca T, Walter S, et al. Subcortical and medial temporal MR-detectable metabolite abnormalities in unipolar major depression. Eur Arch Psychiatry Clin Neurosci 2006; 16.
58. Gidron Y, Ronson A. Psychosocial factors, biological mediators, and cancer prognosis: a new look at an old story. Curr Opin Oncol 2008; 20: 386-92.
59. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005; 10 Suppl 1: 10-23.
60. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-isoprostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004;109: 843-848.
61. Elesbar AA, Best PJ, Lennon RJ, et al. Plasma 8-iso-prostaglandin F2alpha, a marker of oxidative stress, is increased in patients with acute myocardial infarction. Free Radic Res 2006; 40: 385-391.
62. Davì G, Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 2005; 14: 760-764.
63. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006; 27: 24-31.
64. Babior BM. Phagocytes and oxidative stress. Am. J. Med 2000; 109: 33-44.
65. Memon RA, Staprans I, Noor M, et al. Infection and inflamemation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol 2000; 20: 1536-1542.
66. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 2010; 125: 287-94.
67. Wolkowitz OM, Mellon SH, Epel ES, et al. Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress-preliminary findings. PLoS One 2011; 6: 17837.
68. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaraglu G, Deger O. Anti-oxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect Disord 2001; 46: 43-51.
69. Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007; 38: 247-52
70. Srivastava N, Barthwal MK, Dalal PK, et al. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affective Disorders 2002; 72: 45-52.
71. Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affective Disorders 2004; 80: 249-56.
72. Van Hunsel F, Wauters A, Vandoolaeghe E, Neels H, Demedts P, Maes M. Lower total serum protein, albumin, and beta-and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments. Psychiatry Research 1996; 65: 159-69.
73. Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatrica 2004; 16: 200-3.
74. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Human Psychopharmacology 2007; 22, 67-73.
75. Herken H, Gurel A, Selek S, et al. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch Med Res 2007; 38: 247-52.
76. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-20-deoxyguanosine in clinical depression. Psychosom. Med 2006; 68: 1-7.
77. Maes M, De Vos N, Pioli R, et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defences in that illness. J Affective Disorders 2000; 58: 241-6.
78. Owen AJ, Batterham MJ, Probst YC, Grenyer BF, Tapsell LC. Low plasma vitamin E levels in major depression: diet or disease? European J Clinical Nutrition 2005; 59: 304-6.
79. Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatrica 2004; 16: 200-3.
80. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol 2008; 11: 851-76.
81. Wang JF, Shao L, Sun X, Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11: 523-9.
82. Kodydková J, Vávrová L, Zeman M, et al. Anti-oxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 2009; 42:1368-74.
83. Fridovich, I. Biological effects of the superoxide radical. Archives of Biochemistry and Biophysics 1986; 247: 1-11.
84. Papadopoulos MC, Koumenis IL, Yuan TY, Giffard RG. Increasing vulnerability of astrocytes to oxidative injury with age despite constant antioxidant defences. Neuroscience 1998; 82: 915-25.
85. Lindenau J, Noack H, Possel H, Asayama K, Wolf G. Cellular distribution of superoxide dismutases in the rat CNS. Glia 2000; 29: 25-34.
86. Rajkowska, G. Post-mortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biological Psychiatry 2000; 48: 766-77.
87. Harrison, PJ. The neuropathology of primary mood disorder. Brain 2002; 125: 1428-49.
88. Soares JC, Mann JJ. The anatomy of mood disorders - review of structural neuroimaging studies. Biol Psychiatry 1997; 41: 86-106.
89. Parashos IA, Tupler LA, Blitchington T, Krishnan KR. Magneticresonance morphometry in patients with major depression. Psychiatry Res 1998; 84: 7-15.
90. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813-29.
91. Murata T, Suzuki R, Higuchi T, Oshima A (2000) Regional cerebral blood flow in the patients with depressive disorders. Keio J Med 2000; 49: 112-13.
92. Oda K, Okubo Y, Ishida R, et al. Regional cerebral blood flow in depressed patients with white matter magnetic resonance hyperintensity. Biol Psychiatry 2003; 53: 150-6.
93. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516-8.
94. Germain A, Nofzinger EA, Kupfer DJ, Buysse DJ. Neurobiology of non-REM sleep in depression: further evidence for hypofrontality and thalamic dysregulation. Am J Psychiatry; 161:1856-63.
95. Holthoff VA, Beuthien-Baumann B, Zundorf G, et al. Changes in brain metabolism associated with remission in unipolar major depression. Acta Psychiatr Scand; 110:184-94.
96. Milak MS, Parsey RV, Keilp J, Oquendo MA, Malone KM, Mann JJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry 2005; 62: 397-408.
97. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90: 1279-83.
98. Penninx BW, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the health, aging and body composition study. Biol. Psychiatry 2003; 54: 566-72.
99. Lesperance F, Frasure-Smith N, Throux P, Irwin M. The association between major depression and levels of soluble inter-cellular adhesion molecule-1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am. J. Psychiatry 2004; 161: 271-7.
100. Ranjit N, Diez-Roux AV, Shea S, et al. Psychosocial factors and inflamemation in the multi-ethnic study of atherosclerosis. Arch. Intern. Med 2007; 167: 174-81.
101. Miller GE, Freedland KE, Duntley S, Carney RM. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am. J. Cardiol 2005; 95: 317-21.
102. Memon RA, Staprans I, Noor M, et al. Infection and inflamemation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol 2000; 20: 1536-42.
103. Zhang R, Brennan ML, Zhongshou S, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J. Biol. Chem 2002; 277: 46116-22.
104. Atmaca M, Tezcan E, Kuloglu M, Ustundag B, Tunckol H. Antioxidant enzyme and malondialdehyde values in social phobia before and after citalopram treatment. European Archives of Psychiatry and Clinical Neuroscience 2004; 254: 231-5.
105. Kotan VO, Sarandol E, Kirhan E, Ozkaya G, Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1284-90.
106. Galecki P, Szemraj J, Bieńkiewicz M, Florkowski A, Galecka E. Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 2009; 61: 436-47.
107. Galecki P, Szemraj J, Bieńkiewicz M, Zboralski K, Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009; 24: 277-86.
108. Michalakeas CA, Parissis JT, Douzenis A, et al. Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. J Card Fail 2011; 17: 748-54.
109. Han YS, Lee CS. Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells. Eur J Pharmacol 2009; 604: 36-44.
110. Moreno-Fernandez AM, Cordero MD, Garrido-Maraver J, et al. Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. J Psychiatr Res 2011 Nov 25.e-pub first
111. Pal SN, Dandiya PC. Glutathione as a cerebral substrate in depressive behaviour. Pharmacol Biochem Behav 1994; 48: 845-51
112. Eren I, Naziroglu M, Demirdas A, et al. Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochemical Research 2007; 32: 497-505.
113. Djordjevic J, Djordjevic A, Adzic M, Elakovic I, Matic G, Radojcic MB. Fluoxetine affects antioxidant system and promotes apoptotic signalling in Wistar rat liver. Eur J Pharmacol 2011, Mar 21 Epub ahead of print
114. Novío S, Núñez MJ, Amigo G, Freire-Garabal M. Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. Basic Clin Pharmacol Toxicol 2011; 109: 365-71.
115. Eren I, Naziroglu M, Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochemical Research 2007a; 32: 1188-1195.
116. Lee CH, Park JH, Yoo KY, et al. Pre-and post-treatments with escitalopram protect against experimental ischemic neuronal damage via regulation of BDNF expression and oxidative stress. Exp Neurol 2011; 229: 450-9.
117. Pedreañez A, Arcaya JL, Carrizo E, et al. Experimental depression induces renal oxidative stress in rats. Physiol Behav 2011; 104:1002-9.
118. Abdel-Wahab BA, Salama RH. Venlafaxine protects against stressinduced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol Biochem Behav 2011; 100: 59-65.
119. Zafir A, Ara A, Banu N. In vivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 220-8.
120. Garg R, Kumar A Possible role of citalopram and desipramine against sleep deprivation-induced anxiety like-behaviour alterations and oxidative damage in mice. Indian J Exp Biol 2008; 46: 770-6.
121. Moretti M, Colla A, de Oliveira Balen G, et al. Severo Rodrigues AL Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behaviour and brain oxidative damage induced by chronic unpredictable stress. J Psychiatr Res. 2011, 7. Epub first.
122. Lee CS, Han ES, Lee WB. Antioxidant effect of phenelzine on MPP+-induced cell viability loss in differentiated PC12 cells. Neurochemical Research 2003; 28: 1833-1841.
123. Verleye M, Steinschneider R, Bernard FX, Gillardin JM. Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes. Brain Research 2007; 1138: 30-38.
124. Lara DR, Belmonte-de-Abreu P, Souza DO. Allopurinol for refractory aggression and self-inflicted behaviour. J Psychopharmacol 2000; 14: 81-83.
125. Lara DR, Cruz MR, Xavier F, Souza DO, Moriguchi EH. Allopurinol for the treatment of aggressive behaviour in patients with dementia. Int Clin Psychopharmacol 2003; 18: 53-55.
126. Veurink G, Liu D, Taddei K, et al. Reduction of inclusion body pathology in ApoE-deficient mice fed combination of antioxidants. Free Radic Biol Med 2003; 34: 1070-1077.
127. Maes M. Functional or psychosomatic symptoms, e.g. a flulike malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol Lett 2009; 30: 564-73.
128. Michel TM, Frangou S, Camara S, et al. Altered glial cell linederived neurotrophic factor (GDNF) concentration in the brain of patients with depressive disorder: a comparative post-mortem study. Euro Psychiatry 2008; 23:413-20.
129. Mineur YS, Picciotto MR. Biological basis for the co-morbidity between smoking and mood disorders. J Dual Diagns 2009. 5: 122-130.
130. Ettinger U, Williams SC, Patel D, et al. Effects of acute nicotine on brain function in healthy smokers and non-smokers:estimation of inter-individual response heterogeneity 2009. 45: 549-61.
131. Michel TM, Patel D, Kumar A, et al. Effects of acute and chronic nicotine exporsure on plasma NT 3 levels 2010. European Psychiatric Association Conference, München, March 2010.
132. Nickl-Jockschat T, Michel TM. Neurotrophic factors in autism. Molecular Psychiatry 2011; 16: 478-490.
133. Durany N, Michel T, Zochling R, et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001; 52: 79-86.
134. Durany N, Michel T, Jellinger K, et al. Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Devl Neurosci 2000; 18: 807-81.
135. Thome J, Nara K, Foley P, et al. CNTF genotypes: influence on choline acetyltransferase (ChAT) and acetylcholine esterase (AChE) activities and neurotrophin 3 (NT3) concentration in human post mortem brain tissue. J Brain Res 1997; 38: 443-451.
136. Morishiri E, Basti A, Noorbala A, Jamshidi H, Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mildmoderate depression: A double-blind, randomized and placebocontrolled trial. Phytomed 2006; 13; 607-11.